Who
Alastair Garfield
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Rhythm Pharmaceuticals.
In numbers
- Trades disclosed
- 32
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $1.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 8 Jul 2024
- Last trade
- 13 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Jun 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Aug 2026filed 17 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $233K2,007 at $116.11 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $182K1,556 at $117.08 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $402K3,400 at $118.28 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $95K800 at $119.17 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $233K2,007 at $116.11 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $182K1,556 at $117.08 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $402K3,400 at $118.28 | filing |
| 13 Aug 2026filed 17 Aug 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $95K800 at $119.17 | filing |
| 1 Jul 2026filed 2 Jul 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —4,445 | filing |
| 1 Jul 2026filed 2 Jul 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $237K2,150 at $110.41 | filing |
| 1 Jul 2026filed 2 Jul 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,445 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,445 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —4,445 | filing |
| 1 Jul 2026filed 2 Jul 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $237K2,150 at $110.41 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,650 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,650 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —6,663 | filing |
| 1 Feb 2026filed 3 Feb 2026 | RYTM Rhythm PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $221K2,026 at $108.99 | filing |
News
Contrasting Rhythm Pharmaceuticals (NASDAQ:RYTM) & ADMA Biologics (NASDAQ:ADMA)RYTM · dailypolitical.com · 22 Oct 2026Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic ObesityRYTM · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Alastair Garfield; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.